Childhood Linear IgA Dermatosis Successfully Treated with the Combination of Dapsone and Sulfasalazine.

IF 0.9 Q4 DERMATOLOGY
Case Reports in Dermatology Pub Date : 2025-05-03 eCollection Date: 2025-01-01 DOI:10.1159/000546155
Ashley S Kim, Olav Sundnes
{"title":"Childhood Linear IgA Dermatosis Successfully Treated with the Combination of Dapsone and Sulfasalazine.","authors":"Ashley S Kim, Olav Sundnes","doi":"10.1159/000546155","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Linear IgA dermatosis (LAD) is a rare subepidermal autoimmune blistering skin disorder characterized by the linear deposition of IgA along the basal membrane. It affects primarily young children and adults, and is the most common bullous disease in the paediatric population. Dapsone represents the mainstay of treatment, to which the majority of patients show excellent initial responses with long-term remission. In recalcitrant cases, sulfonamides (sulfapyridine, sulfasalazine, sulfamethoxypyridazine) are considered second-line options either as monotherapy or in conjunction with dapsone. Most published cases of sulfonamides in childhood LAD report use of sulfapyridine or sulfamethoxypyridazine, with no published reports on sulfasalazine use in young children.</p><p><strong>Case presentation: </strong>We present a case of a 1-year-old child with confirmed LAD who did not respond adequately to dapsone alone. Sulfapyridine is not available in Norway, while sulfasalazine is accessible and considered a safe option for other autoimmune disorders. The addition of sulfasalazine resulted in rapid complete remission.</p><p><strong>Conclusion: </strong>This case thus supports sulfasalazine as a pragmatic, accessible alternative to sulfapyridine as the second-line treatment in childhood LAD.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"17 1","pages":"185-190"},"PeriodicalIF":0.9000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140607/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000546155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Linear IgA dermatosis (LAD) is a rare subepidermal autoimmune blistering skin disorder characterized by the linear deposition of IgA along the basal membrane. It affects primarily young children and adults, and is the most common bullous disease in the paediatric population. Dapsone represents the mainstay of treatment, to which the majority of patients show excellent initial responses with long-term remission. In recalcitrant cases, sulfonamides (sulfapyridine, sulfasalazine, sulfamethoxypyridazine) are considered second-line options either as monotherapy or in conjunction with dapsone. Most published cases of sulfonamides in childhood LAD report use of sulfapyridine or sulfamethoxypyridazine, with no published reports on sulfasalazine use in young children.

Case presentation: We present a case of a 1-year-old child with confirmed LAD who did not respond adequately to dapsone alone. Sulfapyridine is not available in Norway, while sulfasalazine is accessible and considered a safe option for other autoimmune disorders. The addition of sulfasalazine resulted in rapid complete remission.

Conclusion: This case thus supports sulfasalazine as a pragmatic, accessible alternative to sulfapyridine as the second-line treatment in childhood LAD.

氨苯砜联合柳氮磺胺吡啶成功治疗儿童线性IgA皮肤病。
线性IgA皮肤病(LAD)是一种罕见的表皮下自身免疫性起疱性皮肤病,其特征是IgA沿基底膜呈线性沉积。它主要影响幼儿和成人,是儿科人群中最常见的大疱性疾病。氨苯砜是主要的治疗方法,大多数患者表现出良好的初始反应和长期缓解。在顽固性病例中,磺胺类药物(磺胺吡啶、磺胺嘧啶、磺胺甲氧基吡啶)被认为是二线选择,可作为单一治疗或与氨苯砜联合使用。大多数已发表的儿童LAD中磺胺类药物的病例报告使用磺胺吡啶或磺胺甲氧基吡啶,没有关于幼儿使用磺胺吡啶的已发表报告。病例介绍:我们提出一个病例1岁儿童确诊LAD谁没有充分响应单独氨苯砜。在挪威没有磺胺吡啶,而柳氮磺胺吡啶可以获得,并且被认为是治疗其他自身免疫性疾病的安全选择。添加柳氮磺胺吡啶导致快速完全缓解。结论:本病例支持柳氮磺胺吡啶作为儿童LAD的二线治疗方案,是一种实用的、可获得的替代方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
57
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信